Verrica Pharmaceuticals Inc. has expanded its international presence through a partnership with Torii Pharmaceutical Co. Ltd., resulting in the launch of YCANTH® for the treatment of molluscum contagiosum in Japan. As part of this collaboration, Verrica has initiated a manufacturing transfer process to Torii for YCANTH applicators, a transition expected to take several years. During this period, Verrica will supply applicators to Torii and receive a transfer price, eventually moving to a royalty-based model once manufacturing is established in Japan. This development follows the approval of YCANTH in Japan by the Ministry of Health, Labour and Welfare, underscoring Verrica’s commitment to expanding its global footprint and addressing unmet needs in dermatology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651094) on February 09, 2026, and is solely responsible for the information contained therein.